普瑞巴林依赖、戒断、自杀倾向与精神病性事件报告:澳大利亚不良事件数据库的不比例分析
该研究基于澳大利亚治疗用品管理局2005至2024年收到的病例报告,采用不比例分析比较普瑞巴林与其他药物及同类神经病理性疼痛药物在依赖、戒断、自杀倾向和精神病性事件方面的报告信号。结果显示普瑞巴林相对所有其他药物在药物滥用与依赖、戒断、自杀与自伤、精神病性障碍方面均呈强不比例报告信号;与同类药物相比,药物滥用与依赖及精神病性障碍的信号仍存在但较弱。
要点
- 普瑞巴林相对所有其他药物在药物滥用与依赖、戒断、自杀与自伤、精神病性障碍方面均呈强不比例报告信号。
- 与加巴喷丁、度洛西汀和阿米替林相比,普瑞巴林在药物滥用与依赖及精神病性障碍方面仍呈不比例报告信号。
- 临床应关注普瑞巴林使用者的依赖、戒断、自杀倾向及精神病性症状风险。
核心结论
- 普瑞巴林相对其他药物(包括其他神经病理性疼痛药物)在药物依赖和精神病性事件方面报告率更高,提示潜在担忧需进一步研究。
研究设计与样本
- 研究采用不比例分析,数据来源于2005至2024年澳大利亚治疗用品管理局收到的涉及依赖、戒断、自杀倾向和精神病性事件的不良事件病例报告。
主要发现
- 与数据库中所有其他药物相比,普瑞巴林在药物滥用与依赖(ROR=13.53,95%CI:12.12,15.10)、药物戒断(ROR=6.76,95%CI:4.99,9.15)、自杀与自伤(ROR=12.40,95%CI:10.71,14.36)、精神病与精神病性障碍(ROR=5.81,95%CI:4.99,6.76)方面均呈强不比例报告信号。
- 与加巴喷丁、度洛西汀和阿米替林等同类神经病理性疼痛药物相比,普瑞巴林在药物滥用与依赖(ROR=1.38,95%CI:1.17,1.62)和精神病与精神病性障碍(ROR=1.26,95%CI:1.002,1.57)方面仍呈不比例报告信号,但效应较弱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Globally, Australia has the highest per capita consumption rate of pregabalin, commonly prescribed for neuropathic pain. Emerging evidence suggests pregabalin may be associated with the onset or recurrence of several potentially life-threatening psychiatric events in some individuals. METHODS: We conducted disproportionality analyses using case reports involving adverse events related to dependence, withdrawal, suicidality and psychosis, submitted to Australia's Therapeutic Goods Administration between 2005 and 2024. Reporting odds ratios (RORs) were calculated to determine whether these adverse events were disproportionately reported for pregabalin compared to all other drugs in the database and to an active comparator group of other neuropathic pain drugs (gabapentin, duloxetine and amitriptyline). RESULTS: Compared to all other drugs in the database, pregabalin showed strong signals of disproportionate reporting for drug abuse and dependence (ROR = 13.53, 95% confidence interval [CI]: 12.12, 15.10), drug withdrawal (ROR = 6.76, 95% CI: 4.99, 9.15), suicide and self-injury (ROR = 12.40, 95% CI: 10.71, 14.36), and psychosis and psychotic disorders (ROR = 5.81, 95% CI: 4.99, 6.76). When compared to other neuropathic pain drugs, the signal of disproportionate reporting remained for drug abuse and dependence (ROR = 1.38, 95% CI: 1.17, 1.62) and psychosis and psychotic disorders (ROR = 1.26, 95% CI: 1.002, 1.57), albeit with less pronounced effects. CONCLUSIONS: Adverse events related to drug dependence and psychosis are reported to the Australian pharmacovigilance database at a higher rate for pregabalin compared to other drugs, including other neuropathic pain drugs, signalling a potential concern that warrants further investigation.
引用
- McNeilage AG, Gholamrezaei A, Murnion B, et al. Pregabalin dependence, withdrawal, suicidality and psychosis reports: A disproportionality analysis of the Australian adverse events database. Br J Clin Pharmacol. 2025. PMID: 40999886. doi:10.1002/bcp.70279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。